Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The combination of tigatuzumab and gemcitabine inhibits tumor growth in murine pancreatic xenografts. Th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2013
Konular:
Clinical Cancer Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3892397/
https://ncbi.nlm.nih.gov/pubmed/24403266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.137
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller